InvestorsHub Logo
Followers 1323
Posts 22670
Boards Moderated 3
Alias Born 11/15/2011

Re: None

Friday, 11/12/2021 4:51:30 PM

Friday, November 12, 2021 4:51:30 PM

Post# of 27552
iBio uses its proprietary FastPharming Expressions System and know how to develop or manufacture recombinant proteins on a contract
basis for third parties, as well as to support our own biopharmaceutical development initiatives. iBio generated $2.4 million in revenue
from its CDMO service offerings for the year ended June 30, 2021. Fiscal year 2021 revenue increased 50% over revenue of $1.6 million
from the year ended June 30, 2020.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IBIO News